Interim update from a phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory follicular lymphoma

Category Primary study
JournalHematological Oncology
Year 2019
This article has no abstract
Epistemonikos ID: 22822547f91c212dfc25b6b40fe3198e55d7be13
First added on: Feb 11, 2025